Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.
Adenosine Monophosphate
/ analogs & derivatives
Airway Remodeling
Alanine
/ analogs & derivatives
Animals
Antiviral Agents
/ pharmacology
Bronchi
/ drug effects
COVID-19
/ immunology
Chlorocebus aethiops
Diltiazem
/ pharmacology
Drug Synergism
Humans
Immunity, Innate
Models, Biological
Nose
/ drug effects
Respiratory Mucosa
/ drug effects
SARS-CoV-2
/ drug effects
Vero Cells
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
cell ultrastructure remodeling
coronavirus
diltiazem
drug combination
innate immune response
remdesivir
repurposing
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 07 2020
21 07 2020
Historique:
received:
22
04
2020
revised:
01
06
2020
accepted:
26
06
2020
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
25
8
2020
Statut:
ppublish
Résumé
In the current COVID-19 pandemic
Identifiants
pubmed: 32835306
doi: 10.1016/j.xcrm.2020.100059
pii: S2666-3791(20)30075-6
pii: 100059
pmc: PMC7373044
doi:
Substances chimiques
Antiviral Agents
0
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Diltiazem
EE92BBP03H
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100059Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
A.P., B.P., T.J., A.T., O.T., and M.R.-C. are co-inventors of a patent application filed by INSERM, CNRS, Université Claude Bernard Lyon 1, and Signia Therapeutics for the repurposing of diltiazem for the treatment of SARS-CoV-2 infections (FR 20/02351). A.P., O.T., and M.R.-C. are co-founders of Signia Therapeutics SAS. S.C. is the founder of Epithelix, the developer and provider of MucilAir HAE. F.-X.L. has received funding for lectures from Gilead Sciences and Merck Sharp & Dohme France, and funding for travel to meetings from Merck Sharp & Dohme France, Astellas, and Eumedica. B.L. is the co-chair of the Global Influenza and RSV Initiative and the chair of the scientific committee of the Global Influenza Hospital Surveillance Network. B.L. received no personal remuneration for these activities. B.L. received travel grants to attend meetings by Abbott, Seegene, Sanofi, and bioMérieux. All of the other authors declare no competing interests.
Références
Emerg Infect Dis. 2004 Feb;10(2):320-6
pubmed: 15030705
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
PLoS Biol. 2008 Sep 16;6(9):e226
pubmed: 18798692
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Gen Virol. 2013 Aug;94(Pt 8):1749-1760
pubmed: 23620378
Influenza Other Respir Viruses. 2015 Jan;9(1):51-7
pubmed: 25482367
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Clin Immunol. 2020 Jan;210:108312
pubmed: 31760096
J Med Virol. 2020 Jun;92(6):568-576
pubmed: 32134116
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
PLoS One. 2010 Jun 17;5(6):e11159
pubmed: 20567522
Sci Rep. 2019 Aug 7;9(1):11493
pubmed: 31391513
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antiviral Res. 2018 Aug;156:72-79
pubmed: 29890184
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2019 Jan 29;10:60
pubmed: 30761132
J Gen Virol. 1979 Apr;43(1):247-52
pubmed: 113494
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Virchows Arch. 1994;424(3):295-300
pubmed: 8186894
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166